CA-VELODYNE-LIDAR
30.7.2020 14:02:16 CEST | Business Wire | Press release
Velodyne Lidar, Inc. today announced that Emesent’s newly introduced Autonomy Level 2 (AL2) technology for Hovermap uses Velodyne lidar sensors to provide real-time perception and high-quality, accurate 3D data. Hovermap is a plug-and-play mapping and autonomy payload for industrial drones that enables autonomous flight in areas beyond visual line of sight (BVLOS) and without GPS connectivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200730005182/en/
The AL2 technology uses Velodyne’s Puck LITE lidar as the primary perception and mapping sensor. This allows autonomous exploration, navigation and lidar mapping in challenging inaccessible environments such as mines, civil construction works, telecommunications infrastructure and disaster response environments. As part of Emesent’s simultaneous localization and mapping (SLAM) based autonomy stack, AL2 powers drones to fly beyond communications range, self-navigate and avoid obstacles including thin wires and branches.
AL2 can be operated from take-off to landing by setting smart waypoints in a live 3D map streamed to a tablet. This allows operators to remain a safe distance from hazardous environments such as brows, stope edges, confined spaces and heights. The rich data from the Puck LITE sensor enables companies to gain better data insights on how to make mines and other environments safe.
“The Velodyne Puck LITE is simply a sensational sensor for creating drone-based mapping and autonomy solutions because of its compact size, light weight and performance – all critical for drone-mounted systems,” said Dr. Stefan Hrabar, Emesent CEO. “The sensor was an essential ingredient in helping us to create game-changing new technology that can obtain vital data in challenging environments in real time without risking the machine or operator safety.”
Emesent is an Automated with Velodyne partner at the forefront of GPS-denied drone autonomy. The company recently placed fourth in the urban circuit of the DARPA Subterranean (“SubT”) Challenge together with the Robotics and Autonomous Systems Group at the Commonwealth Scientific and Industrial Research Organization (CSIRO) and Georgia Institute of Technology.
“Emesent’s innovative use of Velodyne’s lidar sensors is helping to deliver valuable data and insights that were previously impossible to access,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “In addition to what they provide today to the mining, infrastructure, survey and mapping industries, it is exciting to consider how this innovation will help usher in a new era of autonomous drone operation across a variety of other industries.”
In the United States, the Federal Aviation Administration (FAA) currently has restrictions on drones flying beyond the visual line of sight. Emesent’s technology innovation could potentially usher in a new era of safe, autonomous drone flight – not only in mines but everywhere.
Velodyne Puck LITE sensors deliver a high-resolution image to measure and analyze indoor and outdoor environments. Designed for applications that require a sensor with a low weight and compact size, the Puck LITE delivers outstanding resolution and performance for mobile and UAV/drone applications. It provides a full 360-degree environmental view to deliver real-time 3D data.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
About Emesent
Emesent is a world-leader in drone autonomy, lidar mapping and data analytics. Founded in 2018, Emesent has since built a reputation for delivering high-quality data capture in the mining, infrastructure, survey and mapping industries. Their flagship product, Hovermap, is a smart mobile scanning unit that combines advanced collision avoidance and autonomous flight technologies to map hazardous and GPS-denied environments. Hovermap is uniquely versatile, it can be handheld, drone- or vehicle-mounted to map challenging, inaccessible areas. With a wide range of applications, Hovermap is being used by customers around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200730005182/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom